Technology | April 19, 2012

FDA Clears GE’s Q. Freeze for PET/CT to Better Assess Cancer Treatment Response

Q.Freeze imaging technology can eliminate a patient’s respiratory motion within PET/CT imaging, potentially saving healthcare costs

April 19, 2012 — GE Healthcare this week announced it has received U.S. Food and Drug Administration (FDA) clearance of Q.Freeze, one of the positron emission tomography/computed tomography (PET/CT) quantitative imaging technologies designed to enable treatment evaluation earlier in a patient’s cancer treatment.

Q.Freeze combines the quantitative benefits of 4-D phase-matched PET/CT imaging, MotionMatch, into a single static image. By collecting CT and PET data at each phase of the breathing cycle, then matching the data for attenuation correction purposes, Q.Freeze is designed to improve quantitative consistency compared to conventional static PET imaging techniques while facilitating the reading of the 4D PET/CT imaging. None of the acquisition data is wasted, as 100 percent of the counts collected are combined to create a single static image. The goal is an image that has the dual benefit of frozen patient respiratory motion and reduced image noise.

The spark behind the idea — which has been under development since 2006 — was that correcting for lesion movement tied to respiratory motion at the same comfort and dose level as a routine static procedure would support clinicians’ diagnostic confidence. Because patients may not breathe the same way as they might have during their baseline study, Q.Freeze could help enable easy and proper longitudinal response to therapy comparisons.

“GE Healthcare has demonstrated its excellence in addressing one of the biggest clinical challenges in PET/CT: respiratory motion” said Michael Barber, vice president and general manager, molecular imaging, GE Healthcare. “Respiratory motion impacts image clarity and quantification accuracy of lesions in organs subject to respiratory motion, such as the lung, liver and pancreas. Now with Q.Freeze, GE Healthcare is offering an innovative technology that makes patient respiratory motion correction a routine procedure for every scan.”

In a recent study by Cristina Messa, head of the nuclear medicine department, and Luca Guerra, nuclear medicine physician of the Center for Molecular Bioimaging and San Gerado Hospital (HSG-CBM) in Monza, Italy, a patient underwent PET/CT for nodule characterization. Their findings included a comparison of static acquisition, 4-D PET/CT acquisition and Q.Freeze acquisition to determine clear evidence of a metabolic lesion. The Q.Freeze acquisition was able to increase image quality, making the lesion easily identifiable. According to the doctors, this improvement leads to a potential workflow benefit, allowing the physician to review only one set of images free of a patient’s respiratory motion.

Q.Freeze is included in the GE Healthcare Q.Suite, a collection of next-generation capabilities designed to further quantitative PET by generating more consistent standardized uptake value (SUV) readings — enabling clinicians to assess treatment response accurately. During the course of cancer treatment, clinicians traditionally gauge progress by looking for physical change in the size of a tumor, typically using computed tomography (CT) or magnetic resonance (MR). However, with quantitative PET imaging, they are also able to consider a tumor’s metabolic activity. In many cases, metabolic changes in a tumor can be perceived earlier than physical ones; thus quantitative PET can give physicians an earlier view of how well a treatment is working.

For quantitative PET to be effective, consistency of SUV measurements between a patient’s baseline scan and subsequent follow-up scans is critical. Variation can occur throughout the PET workflow, in areas from patient management and biology to equipment protocols and performance. Controlling these variables to increase consistency can improve the clinician’s confidence that an SUV change has true clinical meaning.

“Doctors are seeking quantitative tools, such as Q.Freeze, to obtain reproducible measurements over a longitudinal patient study. Q.Freeze is one of the first element of a suite of tools that may enable doctors to assess confidently biological changes in a patient during a course of treatment, allowing them to quickly and accurately modify treatment regimens,” said Vivek Bhatt, general manager, PET/CT, GE Healthcare. “These tools, ultimately, could potentially contribute to personalized oncology care, increase quality of patient care and reduce wasted expenditure on ineffective treatment.”

For more information: www.gehealthcare.com

Related Content

Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init